UPDATE: Piper Jaffray Initiates Coverage on Chimerix as 2014 Biotech Sector Outlook Remains Strong
November 27, 2013 at 10:41 AM EST
In a report published Wednesday, Piper Jaffray analyst Joshua E. Schimmer initiated coverage on Chimerix (NASDAQ: CMRX ) with an Overweight rating and $33.00 price target. In the report, Piper Jaffray noted, “We are initiating, resuming or assuming coverage on 16 biotechnology companies. We believe the outlook for the biotech
